文献速递膀胱癌与上尿路尿路上皮癌

上尿路尿路上皮癌肾输尿管切除术后变异组织学的预后价值:系统综述与荟萃分析

Prognostic Value of Variant Histology in Upper Tract Urothelial Carcinoma Treated with Nephroureterectomy: A Systematic Review and Meta-Analysis.
PubMed 文献 · J Urol · 2019-09-03

该系统综述与荟萃分析检索多个数据库,纳入32项研究共16052例接受根治性肾输尿管切除术的上尿路尿路上皮癌患者,其中26项研究12865例进入荟萃分析。结果显示变异组织学与更差的肿瘤特异性生存、总生存和无复发生存相关,微乳头型及鳞状/腺样变异亚组中变异组织学与肿瘤特异性生存独立相关。

要点

  • 变异组织学与上尿路尿路上皮癌患者肿瘤特异性、总生存及无复发生存差相关
  • 微乳头型变异组织学患者肿瘤特异性生存的合并HR为3.02
  • 鳞状和/或腺样变异组织学患者肿瘤特异性生存的合并HR为1.48

核心结论

  • 上尿路尿路上皮癌中变异组织学与肿瘤特异性死亡、总死亡及疾病复发风险增加相关。
  • 微乳头型及鳞状和/或腺样变异组织学亚组中,变异组织学与肿瘤特异性生存独立相关。

研究设计与样本

  • 系统综述与荟萃分析,检索PubMed、Web of Science、Cochrane Library和Scopus数据库(2019年5月),遵循PRISMA声明。
  • 共纳入32项研究16052例患者,其中26项研究12865例患者符合荟萃分析条件。

主要发现

  • 变异组织学与肿瘤特异性生存差相关(合并HR 2.00,95% CI 1.57至2.56)。
  • 变异组织学与总生存差相关(合并HR 1.76,95% CI 1.51至2.04)。
  • 变异组织学与无复发生存差相关(合并HR 1.64,95% CI 1.42至1.89)。
  • 微乳头型变异组织学与肿瘤特异性生存差相关(合并HR 3.02,95% CI 1.71至5.34)。
  • 鳞状和/或腺样变异组织学与肿瘤特异性生存差相关(合并HR 1.48,95% CI 1.14至1.92)。

临床怎么用

  • 考虑将变异组织学纳入上尿路尿路上皮癌的预后评估工具,以辅助患者和医生选择适当的治疗策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We sought to assess the prognostic value of variant histology in patients with upper tract urothelial carcinoma treated with radical nephroureterectomy. MATERIALS AND METHODS: We searched PubMed®, Web of Science™, Cochrane Library and Scopus® databases in May 2019 according to the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) statement. Studies were deemed eligible if they compared overall, cancer specific and recurrence-free survival in patients with upper tract urothelial carcinoma with or without variant histology. Formal meta-analyses were performed for these outcomes. RESULTS: We identified 32 studies with 16,052 patients, including 26 studies with 12,865 patients that were eligible for the meta-analysis. Variant histology was associated with poor outcomes in terms of cancer specific (pooled HR 2.00, 95% CI 1.57 to 2.56), overall (pooled HR 1.76, 95% CI 1.51 to 2.04) and recurrence-free survival (pooled HR 1.64, 95% CI 1.42 to 1.89). Subgroup analyses revealed that micropapillary (pooled HR 3.02, 95% CI 1.71 to 5.34), and squamous and/or glandular variant histologies (pooled HR 1.48, 95% CI 1.14 to 1.92) were also associated with poor cancer specific survival. CONCLUSIONS: Variant histology in patients with upper tract urothelial carcinoma is associated with an increased risk of cancer specific and overall mortality and disease recurrence. Furthermore, variant histology was independently associated with cancer specific survival in the micropapillary, and squamous and/or glandular variant histology subgroups. It may be useful to incorporate variant histology into prognostic tools that help guide patients and physicians in selecting appropriate treatment strategies for upper tract urothelial carcinoma.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Mori K, Janisch F, Parizi MK, et al. Prognostic Value of Variant Histology in Upper Tract Urothelial Carcinoma Treated with Nephroureterectomy: A Systematic Review and Meta-Analysis. J Urol. 2019. PMID: 31479406. doi:10.1097/JU.0000000000000523

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。